Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis.
Emerging data suggest that metastasis-associated protein 1 (MTA1) represses ligand-dependent transactivation functions of estrogen receptor-alpha in cultured breast cancer cells and that MTA1 is upregulated in human breast tumors. However, the role of MTA1 in tumorigenesis in a physiologically relevant animal system remains unknown. To reveal the role of MTA1 in mammary gland development, transgenic mice expressing MTA1 under the control of the mouse mammary tumor virus promoter long terminal repeat were generated. Unexpectedly, we found that mammary glands of these virgin transgenic mice exhibited extensive side branching and precocious differentiation because of increased proliferation of ductal and alveolar epithelial cells. Mammary glands of virgin transgenic mice resemble those from wild-type mice in mid-pregnancy and inappropriately express beta-casein, cyclin D1 and beta-catenin protein. Increased ductal growth was also observed in the glands of ovariectomized female mice, as well as of transgenic male mice. MTA1 dysregulation in mammary epithelium and cancer cells triggered downregulation of the progesterone receptor-B isoform and upregulation of the progesterone receptor-A isoform, resulting in an imbalance in the native ratio of progesterone receptor A and B isoforms. MTA1 transgene also increased the expression of progesterone receptor-A target genes Bcl-XL (Bcl2l1) and cyclin D1 in mammary gland of virgin mice, and, subsequently, produced a delayed involution. Remarkably, 30% of MTA1 transgenic females developed focal hyperplastic nodules, and about 7% exhibited mammary tumors within 18 months. These studies establish, for the first time, a potential role of MTA1 in mammary gland development and tumorigenesis. The underlying mechanism involves the upregulation of progesterone receptor A and its targets, Bcl-XL and cyclin D1.
Bagheri-Yarmand
Rozita
R
Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Talukder
Amjad H
AH
Wang
Rui-An
RA
Vadlamudi
Ratna K
RK
Kumar
Rakesh
R
D000818:Animals; D015152:Blotting, Northern; D015139:Blotting, Southern; D001973:Bromodeoxyuridine / Q000494:pharmacology; D002455:Cell Division; D019938:Cyclin D1 / Q000378:metabolism; D005260:Female; D018507:Gene Expression Regulation, Developmental; D006655:Histone Deacetylases / Q000502:physiology*; D015151:Immunoblotting; D020287:In Situ Nick-End Labeling; D008297:Male; D008321:Mammary Glands, Animal / Q000196:embryology*; D015674:Mammary Neoplasms, Animal / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D008957:Models, Genetic; D020033:Protein Isoforms; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012097:Repressor Proteins / Q000502:physiology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D015534:Trans-Activators; D051020:bcl-X Protein
C494812:Bcl2l1 protein, mouse; C089320:MTA1 protein, human; D020033:Protein Isoforms; D019253:Proto-Oncogene Proteins c-bcl-2; D011980:Receptors, Progesterone; D012097:Repressor Proteins; D015534:Trans-Activators; D051020:bcl-X Protein; C101118:progesterone receptor A; C097314:progesterone receptor B; D019938:Cyclin D1; D006655:Histone Deacetylases; D001973:Bromodeoxyuridine